Patients with KRAS mutations tend to have a poorer prognosis, and KRAS mutations have been identified as negative prognostic biomarkers. Patients with KRAS mutations appear to have a shorter survival than those with wild-type KRAS. However, KRAS mutational status is not predictive of a lack of chemotherapeutic efficacy, according to NCCN guidelines.
A 2018 meta-analysis indicated that EGFR mutations were significantly associated with improved OS and disease-free survival, whereas KRAS mutations predicted worse disease-free survival and OS in patients with resected NSCLC.
Learn more about the clinical significance of KRAS mutations in NSCLC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan, Maurie Markman. Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer - Medscape - Aug 16, 2022.